



ACCREDITATION DOCUMENT

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 160

Accreditation No: LAB 160

Awarded to

Drug Testing Laboratory
Muzaffar Garrh Road, Near Kidney Center,
Multan, Pakistan

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **31-07-2018** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **30-07-2027**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

PAKISTAN NATIONAL ACCREDITATION COUNCIL

01-07-2024
Date

-SD-
Director General

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
---	-------------------------------	---

Testing Laboratory.

Accreditation Scope of **Drug Testing Laboratory, Muzaffar Garrh Road, Near Kidney Center Multan, Pakistan.**

Permanent laboratory premises

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
Paracetamol Active Pharmaceutical ingredient	Pharmaceutical Testing	Quantitative Analysis	Internal Method /UV-Absorbance/ UV-Visible Spectrophotometer
Paracetamol Tablet Dosage Form	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (1116)
Ibuprofen Active Pharmaceutical ingredient	Pharmaceutical Testing	Quantitative Analysis	Internal Method/Liquid Chromatography/HPLC
Ibuprofen Tablet Dosage Form	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-B108D32E-F28B-41A3-84C7-62D1C4F37646_1_en-US
Paracetamol Tablet Dosage Form	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Ribavirin Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-79E8E419-A69C-48A9-9569-2E152FD4F9DF_1_en-US
Ribavirin Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Allopurinol Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III (131)
Allopurinol Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Mebeverine tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (917)

01-07-2024
Date

-Sd-
Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
---	-------------------------------	---

Ciprofloxacin Infusion	Pharmaceutical Testing	Extractable Volume	USP 2021, (697) GUID-36AE7C6F-5983-4F42-9426-24574CEDB1A4_1_en-US
Ciprofloxacin Infusion	Pharmaceutical Testing	pH	USP 2021, GUID-1563E2BF-7B08-4697-84CB-EE75CA301FE4_3_en-US
Sitagliptin tablet	Pharmaceutical Testing	Disintegration	USP 2021, GUID-6396D7AC-ABBE-49ED-B8F5-C213E832E46B_2_en-US
Water for injection	Pharmaceutical Testing	Conductivity	USP 2021, (645), GUID-4FD1180F-0393-43A1-970D-EB8F59988EB9_1_en-US
Propranolol Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (1212)
Atenolol Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (178)
Furosemide Injection	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (676,677)
Indomethacin Capsule	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (792)
Isotretinoin Capsule	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (835)
Isotretinoin Gel	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (836)
Metformin Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (948)
Naproxen Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (1038)
Dydrogesterone Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (578)
Metronidazole Infusion	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2021, Volume III, (970)
Fluoxetine Capsule	Pharmaceutical Testing	Assay (HPLC)	BP 2021, Volume III (662)

01-07-2024
Date

-Sd-
Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
---	-------------------------------	---

Naproxen Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-E0062EF4-9F01-4B0D-9A46-E1090658060B_2_en-US
Loratadine Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-1957A349-A999-45EE-84BD-DDDF914EA4C7_1_en-US
Amoxicillin Capsule	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-66E62AE3-012A-4BC6-BC6F-859B8542D871_4_en-US
Carvedilol Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-9CC35D41-7DEE-4EE4-AB70-53D51997F081_2_en-US
Candesartan Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-7A644ECE-E09B-4628-9174-7B452CDDC234_4_en-US
Levetiracetam Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-CAC2588F-9536-4FBC-AA54-45C08164A379_4_en-US
Ibuprofen Oral Suspension	Pharmaceutical Testing	Assay (HPLC)	USP 2021, GUID-1031FAFB-4C02-4B6A-94A7-2C71DAAD55BC_1_en-US
Sodium Chloride Infusion	Pharmaceutical Testing	Assay (Titration)	BP 2021, Volume III, (1297), V-A137 Appendix I A.
Metronidazole tablet	Pharmaceutical Testing	Disintegration	BP 2021, Volume III, (972) BP 2021, V-A389, Appendix XII A
Metformin Tablet	Pharmaceutical Testing	Dissolution	BP 2021, Volume III, (948) V-A408 Appendix XIIC
Paracetamol Tablet	Pharmaceutical Testing	Dissolution	BP 2021, Volume III, (1115) V-A408 Appendix XIIC
Naproxen Tablet	Pharmaceutical Testing	Dissolution	BP 2021, Volume III, (1038) V-A408 Appendix XIIC
Acyclovir Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Aminophylline Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Carbimazole Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Metformin Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C

01-07-2024
Date

-Sd-
Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
---	-------------------------------	---

Metoprolol Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Naproxen Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Propranolol Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Fluvoxate Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Ramipril Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Pyridoxine Tablet	Pharmaceutical Testing	Weight Variation	BP 2021, Volume V (A413) Appendix XII C
Amikacin Injection	Pharmaceutical Testing	pH	BP 2021 Volume III (136)
Dexamethasone sodium phosphate Injection	Pharmaceutical Testing	pH	BP 2021 Volume III (507)
Isosorbide Dinitrate Injection	Pharmaceutical Testing	pH	BP 2021 Volume III (827)
Ketamine Injection	Pharmaceutical Testing	pH	BP 2021, Volume III (842)
Mannitol Infusion	Pharmaceutical Testing	pH	BP 2021, Volume III (915)
Metoclopramide Injection	Pharmaceutical Testing	pH	BP 2021, Volume III (962)
Metronidazole Infusion	Pharmaceutical Testing	pH	USP 2021, GUID-CE3907B5-994E-4918-8B41-117C6DC88A28_3_en-US
Midazolam Injection	Pharmaceutical Testing	pH	BP 2021, Volume III (981)
Tranexamic Acid Injection	Pharmaceutical Testing	pH	BP 2021, Volume III (1401)

01-07-2024
Date

-Sd-
Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
---	-------------------------------	---

Valproate Sodium Injection	Pharmaceutical Testing	pH	USP 2021, GUID-8728583B-DD52-4C98-8A46-85077D576202_4_en-US
Metronidazole Injection (100 mL)	Pharmaceutical Testing	Extractable Volume	USP 2021, (697) GUID-36AE7C6F-5983-4F42-9426-24574CEDB1A4_1_en-US
Metronidazole Infusion (100 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Oxytetracycline Injection (50 mL)	Pharmaceutical Testing	Extractable Volume	USP 2021, (697) GUID-36AE7C6F-5983-4F42-9426-24574CEDB1A4_1_en-US
Potassium Chloride Injection (20 mL, 25 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Sodium Bicarbonate Injection (20 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Sodium Chloride Infusion (100 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Sodium Chloride Injection (100 mL)	Pharmaceutical Testing	Extractable Volume	USP 2021, (697) GUID-36AE7C6F-5983-4F42-9426-24574CEDB1A4_1_en-US
Mannitol Infusion (500 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Sulfadimidine Injection (100mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Ciprofloxacin Injection (100 mL)	Pharmaceutical Testing	Sterility Test	USP 2022 / Volume 4 6515 <85>
Ciprofloxacin Injection (100 mL)	Pharmaceutical Testing	Endotoxin Test	USP 2022 / Gel Clot Method, Volume 4 6510 <85>
Domperidone tablet	Pharmaceutical Testing	Weight Variation	BP 2023/ General Chapter Weight Variation, Volume V (A408) Appendix XII C

01-07-2024
Date

-Sd-

Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
---	-------------------------------	---

Flurbiprofen tablet	Pharmaceutical Testing	Weight Variation	BP 2023/ General Chapter Weight Variation, Volume V (A408) Appendix XII C
Mafenamic Acid tablet	Pharmaceutical Testing	Weight Variation	BP 2023/ General Chapter Weight Variation, Volume V (A408) Appendix XII C
Metronidazole tablet	Pharmaceutical Testing	Weight Variation	BP 2023/ General Chapter Weight Variation, Volume V (A408) Appendix XII C
Warfarin tablet	Pharmaceutical Testing	Weight Variation	BP 2023/ General Chapter Weight Variation, Volume V (A408) Appendix XII C
Dobutamine HCl Injection	Pharmaceutical Testing	pH,	USP 2023
Ketorolac Tromethamine Injection	Pharmaceutical Testing	pH,	USP 2023
Sodium Chloride & glucose Infusion	Pharmaceutical Testing	pH,	BP 2023, Volume III
Tramadol HCl Injection	Pharmaceutical Testing	pH,	BP 2023, Volume III
Dobutamine HCl Injection	Pharmaceutical Testing	pH,	USP 2023
Sodium Chloride Infusion	Pharmaceutical Testing	Assay (Titration)	BP 2023, Volume III, V-A122 Appendix I A.
Flurbiprofen Tablet	Pharmaceutical Testing	Assay (UV-Spectroscopy)	BP 2023, Volume III
Ciprofloxacin Infusion	Pharmaceutical Testing	Assay (HPLC)	BP 2023, Volume III

01-07-2024
Date

-Sd-
Director